Haemonetics Co. (NYSE:HAE) EVP Anila Lingamneni Sells 2,305 Shares of Stock

Haemonetics Co. (NYSE:HAE) EVP Anila Lingamneni sold 2,305 shares of the stock in a transaction on Monday, May 6th. The shares were sold at an average price of $95.00, for a total transaction of $218,975.00. Following the sale, the executive vice president now directly owns 12,295 shares of the company’s stock, valued at approximately $1,168,025. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Haemonetics Stock Down 2.0 %

HAE stock opened at $93.25 on Thursday. Haemonetics Co. has a fifty-two week low of $70.74 and a fifty-two week high of $97.13. The company has a market capitalization of $4.74 billion, a price-to-earnings ratio of 37.91, a price-to-earnings-growth ratio of 2.23 and a beta of 0.34. The business’s 50 day moving average price is $83.59 and its two-hundred day moving average price is $82.81. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.76 and a current ratio of 2.92.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.94 by $0.10. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The business had revenue of $336.20 million during the quarter, compared to the consensus estimate of $320.84 million. During the same quarter in the prior year, the company earned $0.85 earnings per share. The firm’s quarterly revenue was up 10.1% compared to the same quarter last year. As a group, analysts forecast that Haemonetics Co. will post 3.95 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Knights of Columbus Asset Advisors LLC increased its stake in shares of Haemonetics by 1.3% during the third quarter. Knights of Columbus Asset Advisors LLC now owns 10,005 shares of the medical instruments supplier’s stock valued at $896,000 after purchasing an additional 128 shares in the last quarter. Parkside Financial Bank & Trust raised its stake in Haemonetics by 17.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,054 shares of the medical instruments supplier’s stock valued at $90,000 after buying an additional 156 shares during the last quarter. Riverwater Partners LLC boosted its holdings in Haemonetics by 1.5% in the fourth quarter. Riverwater Partners LLC now owns 15,784 shares of the medical instruments supplier’s stock worth $1,350,000 after acquiring an additional 231 shares in the last quarter. Arizona State Retirement System boosted its holdings in Haemonetics by 1.7% in the third quarter. Arizona State Retirement System now owns 14,407 shares of the medical instruments supplier’s stock worth $1,291,000 after acquiring an additional 237 shares in the last quarter. Finally, Contravisory Investment Management Inc. grew its stake in shares of Haemonetics by 7.4% in the fourth quarter. Contravisory Investment Management Inc. now owns 3,507 shares of the medical instruments supplier’s stock worth $300,000 after acquiring an additional 242 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Barrington Research reaffirmed an “outperform” rating and set a $105.00 price objective on shares of Haemonetics in a research note on Friday, April 12th. TheStreet lowered Haemonetics from a “b-” rating to a “c+” rating in a research report on Thursday, February 29th. Finally, StockNews.com lowered Haemonetics from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.